Proactive Investors - Run By Investors For Investors

Genedrive to sell contract research and pharmacogenomics divisions for up to £1.9mln

The company's house broker said the price achieved was better than it had expected, although £750,000 of the consideration is dependent on the disposed-of business receiving R&D credits
HCV
The proceeds will provide additional cash to continue to drive the Genedrive platform forward

Genedrive PLC (LON:GDR) is set to pocket up to £1.9mln in cash through the sale of its contract research and pharmacogenomics divisions.

Epistem 2, a company where Genedrive director Dr Catherine Booth is also a director and substantial shareholder, is set to buy the business; Genedrive used to be known as Epistem before it changed its name.

READ: Genedrive surges after receiving £1.1mln in funding to finance development of its TB testing kit

"The disposal of the service business is in line with our stated strategy to focus fully on the near-patient molecular diagnostic market and will provide additional cash to continue to drive the Genedrive platform forward,” said David Budd, the chief executive officer of Genedrive.

"Our diagnostics operations are well positioned having established distribution agreements for our HCV ID kit in a number of major markets, and we have commenced commercial sales to our distributors,” he added.

“We believe Genedrive can play an important role in the diagnosis and management of HCV [hepatitis C) in territories where access to centralised laboratories is limited. We also plan to re-enter the large mTB market and expect to capitalise on other opportunities in markets where Genedrive's speed, cost and accessibility provide tangible benefits to end users," Budd declared.

The price - £1.5mln on the nose and up to £750,000 in deferred consideration – was a bit better than the £1.15mln evenly spread over two years that the house broker had been forecasting.

In terms of the effect on underlying earnings (Ebitda), the division contributed £260,000, including research & development credits, in the 12 months to 30 June 2017 on revenue of £3.16mln.

The first half of the current year saw revenue decline 23.5% from a year earlier to £1.35mln and it made a modest contribution to group profits.

The gross assets attributable to the Services business at the end of June 30 were £1.6mln and the gross liabilities were £831,000. By the end of 2017, the gross assets had declined to £1.05mln with the decline being mostly within the trade debtor balances, while gross liabilities had diminished to £401,000.

The sale will include the transfer of the Epistem name and the company will arrange for the name of Epistem Limited to be changed at completion.

Dr Booth will resign as a director of Genedrive on completion of the disposal and has agreed not to sell any of her Genedrive shares in the first six months after the sale goes through; she has a 5.2% stake in Genedrive.

In mid-morning trading, Genedrive shares were up 2.7% at 38.5p.

 -- Adds share price --

View full GDR profile View Profile

Genedrive PLC Timeline

Related Articles

Hep C
November 22 2018
The company made positive operational progress in the year to June 30.
Callitas CEO James Thompson
July 20 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
bacteria
September 20 2018
Following the disappointment of its DMD treatment over summer, Summit is leveraging its Discuva platform to develop new antibiotics, which doctors are in desperate need of

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use